下调 EGFL8：晚期胃癌的新型生物标志物。
Down-regulation of EGFL8: a novel biomarker for advanced gastric cancer.
机构信息
Department of General Surgery, Guangzhou Red Cross Hospital (Fourth Affiliated Hospital of Jinan University), Guangzhou, China.
出版信息
Anticancer Res. 2011 Oct;31(10):3377-80.
BACKGROUND
Recently, we have reported an important role of epidermal growth factor-like domain 8 (EGFL8) in the progression of colorectal cancer (CRC) and documented EGFL8 to be a novel prognostic biomarker for this malignancy. However, the function of EGFL8 in the other human gastroenterological malignancies such as gastric cancer remains largely unknown.
PATIENTS AND METHODS
EGFL8 expression in 53 cases of gastric cancer and the corresponding normal tissues were determined by quantitative real-time PCR and the EGFL8 down-regulation score for each patient was calculated. Subsequently, the correlations between EGFL8 down-regulation score and the clinicopathological features of gastric cancer were evaluated.
RESULTS
EGFL8 expression was significantly lower in the gastric cancer tissues than the corresponding normal tissues (p=0.0001) and the down-regulation of EGFL8 was evident in 73.6% (39/53) of the gastric carcinomas. More importantly, EGFL8 down-regulation was correlated significantly with peritoneal dissemination (p=0.037) and high TNM stage (p=0.025) of gastric cancer.
CONCLUSION
The down-regulation of EGFL8 might be a novel biomarker for advanced gastric cancer.
背景
最近，我们报道了表皮生长因子样结构域 8（EGFL8）在结直肠癌（CRC）进展中的重要作用，并将 EGFL8 确定为这种恶性肿瘤的一种新的预后生物标志物。然而，EGFL8 在其他人类胃肠道恶性肿瘤（如胃癌）中的作用在很大程度上仍不清楚。
患者和方法
通过实时定量 PCR 测定 53 例胃癌病例及其相应正常组织中的 EGFL8 表达，并计算每位患者的 EGFL8 下调评分。随后，评估 EGFL8 下调评分与胃癌临床病理特征之间的相关性。
结果
胃癌组织中的 EGFL8 表达明显低于相应的正常组织（p=0.0001），在 73.6%（39/53）的胃癌中存在 EGFL8 的下调。更重要的是，EGFL8 的下调与胃癌的腹膜播散（p=0.037）和高 TNM 分期（p=0.025）显著相关。
结论
EGFL8 的下调可能是晚期胃癌的一个新的生物标志物。
Zotero 插件